Customized Solutions for Food Allergy Animal Model

Download

Affecting a significant and growing portion of the global population, food allergy is a pathological, potentially life-threatening immune response triggered by specific food allergens. For biopharmaceutical companies and research institutions advancing therapeutics into this complex space, the translation from target discovery to success demands physiologically relevant preclinical models.

Specializing in the development of customized food allergy animal models, Protheragen offers one-stop solutions, ensuring that each program is supported by scientifically robust data for specific mechanistic studies or objectives.

Overview of Food Allergy Animal Model

Designed to recapitulate the key immunological and features of human food allergies, the food allergy animal model is a specialized platform focused on inducing IgE-mediated, non-IgE-mediated, or mixed hypersensitivity responses. Utilizing established protocols in strains such as BALB/c or C3H/HeJ mice, the model employs relevant food antigens, including peanut, ovalbumin, or milk proteins, administered via sensitization routes followed by challenge phases to elicit hallmark phenotypes. Endpoints are carefully selected to capture systemic anaphylaxis, body temperature drop, mast cell activation, serum IgE levels, and histological changes in the gastrointestinal tract, providing a high-dimensional dataset that mirrors the pathophysiology.

Utilized across both early-stage discovery and late-stage preclinical development, the food allergy animal model serves as a critical tool for de-risking and validating novel immunomodulatory interventions. Its applications are centered on evaluating safety, efficacy, and mechanism of action in a controlled in vivo environment.

Application of Hair-Bearing Skin Organoids

Workflow for Food Allergy Animal Model Development

From early model design through final data delivery, integrated services for food allergy animal model development deliver continuity, consistency, and depth of insight across all phases of a program while maintaining scientific rigor and operational efficiency under a unified platform.

• Custom Model Design: Tailors every aspect of model development to specific program needs, including allergen selection (e.g., peanut, ovalbumin, milk proteins), mouse strain background, sensitization route (oral, intraperitoneal, etc.), and challenge protocols to accurately reflect the intended therapeutic context.
• Full-Study Execution: Conducts all in vivo procedures, including formulation preparation, dosing administration (therapeutic or prophylactic), sample collection (blood, intestinal tissues, spleen, mesenteric lymph nodes), and monitoring, such as anaphylaxis scoring and body temperature measurement.
• Comprehensive Downstream Analysis: Delivers mechanistic insights through integrated bioanalytical services, including histopathology of gastrointestinal tissues, flow cytometry for immune cell phenotyping, and multiplex cytokine/chemokine profiling from serum and tissue homogenates.
• Report Delivery: Produces fully documented efficacy, pharmacokinetic, and pharmacodynamic datasets, with all studies conducted under rigorous quality control and data integrity standards.

Integrated Preclinical Research Services for Food Allergy

Beyond animal model development, a comprehensive suite of preclinical research services is offered to support food allergy programs across all stages of drug development. Each service is designed to integrate seamlessly with custom model platforms, enabling a streamlined workflow from target validation through IND-enabling studies while maintaining scientific rigor and data consistency.

• In Vitro Efficacy Testing Services
• In Vivo Model Development
• PK/PD Study Services
• In Vivo Toxicity Assessment Services
• Biomarker Analysis Services
• And More

Case Study 01-Probiotic Therapy in OVA-induced Model

Protheragen developed a food allergy model to evaluate the therapeutic potential of a probiotic intervention in an OVA-induced murine system. Sensitization was established through subcutaneous administration of OVA adsorbed onto aluminum hydroxide adjuvant, followed by a booster immunization. During the intervention phase, a viable probiotic was delivered daily by intragastric gavage, while allergic reactions were concurrently induced via an OVA-supplemented diet. Then, the comprehensive sample collection is conducted for downstream immunological and histopathological analyses.

Following probiotic therapy, cytokine profiles in intestinal tissue revealed a marked anti-inflammatory effect. Sensitization with OVA led to significant upregulation of the cytokines IL-5, IL-6, and TNF in intestinal homogenates, as measured by ELISA. Administration of the probiotic effectively suppressed the production of these cytokines, demonstrating a shift away from the pro-inflammatory state induced by allergen sensitization. Body weight loss following allergen challenge was also mitigated by the probiotic. Consistent with these findings, serum OVA-specific IgE was elevated in sensitized mice but reduced with therapy. Additionally, eosinophil peroxidase and myeloperoxidase activities in intestinal tissue, markers of eosinophil and neutrophil infiltration, were increased upon sensitization and lowered by probiotic intervention.

Case Study 02-Peanut Allergy Model Development

Protheragen developed a peanut allergy model in C3H/HeJ mice to evaluate anaphylactic responses following allergen sensitization and challenge. Sensitization was established through repeated oral administrations of peanut extract combined with cholera toxin, concluding with a final booster dose, while sham-sensitized controls received vehicle alone. Anaphylaxis was subsequently induced via intraperitoneal injection of peanut extract, after which clinical signs were monitored to assess the severity of the allergic response.

Following peanut sensitization and challenge, robust physiological responses were observed in the model. Serum analysis by ELISA revealed strong induction of peanut-specific IgE, IgG1, and IgG2a in sensitized animals at both weeks 4 and 8, whereas levels remained undetectable in sham-treated controls. A marked elevation in all three immunoglobulin isotypes occurred between the two time points, with increases ranging from 3- to 7-fold. Upon challenge, sensitized mice exhibited pronounced acute allergic responses, including a significant drop in core body temperature measured at 60 minutes post-challenge, alongside elevated symptom scores relative to controls.

Why Choose Us?

• Deep Expertise and Proven Experience: Leverages a dedicated scientific team with extensive experience in food allergy model development across multiple allergen systems and a proven track record of supporting programs from early discovery through preclinical studies.
• Reliable Model Systems: Employs physiologically relevant sensitization and challenge protocols using validated food allergens, generating translational data that closely aligns with human disease endpoints such as core body temperature, anaphylaxis scoring, and comprehensive immunoglobulin profiling.
• End-to-End Solutions: Provides full flexibility in study design, allowing for precise control over allergen type, strain background, sensitization routes, and therapeutic intervention timelines to mirror specific disease indications or therapy modalities.
• Multiparametric Analytical Capabilities: Delivers deep mechanistic insight through integrated analyses, including advanced flow cytometry for immune cell phenotyping, multiplex cytokine/chemokine profiling, and histopathological evaluation of target tissues.

Contact Us

Combining deep scientific expertise with operational flexibility, Protheragen provides a reliable foundation for advancing food allergy therapeutics from concept to clinic through the delivery of high-quality, customized in vivo models. By integrating model development with a full suite of preclinical research services, our services streamline the development timeline while maintaining the rigorous scientific standards required for complex immunology programs. For further details on model specifications or to discuss a specific study design, please contact us to initiate a collaboration.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Rare Disease Diagnostics Development
• Rare Disease Therapeutics Development
• Drug Repurposing Service
• Rare Disease Model Development Services
• Drug Safety Evaluation Services
• Pharmacokinetics Services